MDXH
MDxHealth SA
NASDAQ · Healthcare · Medical - Diagnostics & Research · BE
$0.63
−6.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 156.5M | 107.9M | 90.0M | 70.2M | 37.1M |
| Cost of Revenue | 62.0M | 43.4M | 34.9M | 26.3M | 17.8M |
| Gross Profit | 94.6M | 64.4M | 55.1M | 43.9M | 19.2M |
| Operating Expenses | |||||
| R&D Expense | 20.4M | 10.3M | 10.6M | 6.4M | 7.6M |
| SG&A Expense | 84.6M | 66.8M | 61.4M | 59.9M | 50.1M |
| General & Admin Expense | 65.5M | 59.0M | 55.0M | 23.0M | 23.5M |
| Selling & Marketing Expense | 19.1M | 7.8M | 6.4M | 36.9M | 26.6M |
| Other Expenses | 18.9M | 2.7M | 7.9M | 5.0M | (559.0K) |
| Total Operating Expenses | 123.8M | 79.8M | 79.9M | 71.3M | 57.1M |
| Cost and Expenses | 185.8M | 123.3M | 114.8M | 97.5M | 75.0M |
| Operating Income (EBIT) | (29.3M) | (15.4M) | (24.7M) | (27.3M) | (37.9M) |
| Non-Operating | |||||
| Interest Income | 1.5M | 1.5M | 1.1M | 1.1M | 125.0K |
| Interest Expense | 27.9M | 12.2M | 7.6M | 5.8M | 2.7M |
| Net Interest Income | (26.4M) | (10.7M) | (6.6M) | (4.7M) | (2.6M) |
| Other Non-Op Income/Expense | (25.4M) | (20.0M) | (13.0M) | (15.8M) | (6.1M) |
| Non-Operating Income (excl Interest) | (2.5M) | 7.8M | 5.3M | 10.0M | 3.4M |
| EBT (Pre-Tax Income) | (54.7M) | (35.4M) | (37.7M) | (43.1M) | (44.0M) |
| Income Tax Expense | (1.1M) | (1.9M) | 382.0K | 1.0K | — |
| Bottom Line | |||||
| Net Income | (55.7M) | (33.5M) | (38.1M) | (43.1M) | (44.0M) |
| Earnings from Cont. Ops | (53.7M) | (33.5M) | (38.1M) | (43.1M) | (44.0M) |
| Earnings from Discont. Ops | (2.1M) | — | — | — | — |
| Bottom Line Net Income | (55.7M) | (33.5M) | (38.1M) | (43.1M) | (44.0M) |
| Per Share | |||||
| Basic EPS | ($1.43) | ($0.67) | ($0.78) | ($1.66) | ($2.78) |
| Diluted EPS | ($1.27) | ($0.67) | ($1.16) | ($1.66) | ($2.78) |
| Revenue Per Share | $2.99 | $2.16 | $1.85 | $2.71 | $2.34 |
| Shares | |||||
| Basic Shares Outstanding | 52.4M | 50.0M | 48.7M | 25.9M | 15.9M |
| Diluted Shares Outstanding | 52.4M | 50.0M | 48.7M | 25.9M | 15.9M |
| Profitability Metrics | |||||
| EBITDA | (13.1M) | (14.0M) | (22.0M) | (30.5M) | (36.4M) |
| D&A | 13.7M | 9.2M | 8.0M | 6.9M | 4.9M |
| EBIT | (26.8M) | (23.2M) | (30.1M) | (37.3M) | (41.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026